5 episodes

Biotalk is a deal maker’s playbook to making an impact and generating returns in life sciences. Our guest speakers are industry leaders and institutional and family office investors who share their experience and views on deal making and industry trends to educate and inform.

Biotalk Locust Walk

    • Investing
    • 5.0, 1 Rating

Biotalk is a deal maker’s playbook to making an impact and generating returns in life sciences. Our guest speakers are industry leaders and institutional and family office investors who share their experience and views on deal making and industry trends to educate and inform.

    Biotalk Episode 5, Fred Chereau, LogicBio

    Biotalk Episode 5, Fred Chereau, LogicBio

    In this episode of Biotalk, Josh Hamermesh, VP of Locust Walk interviewed his long lasting friend and colleague, Fred Chereau, CEO of LogicBio. They discussed industry trends on gene therapy and LogicBio recent  $50 million financing to develop novel gene medicines for pediatric patients

    • 38 min
    Episode 4: Stuart Kliman, Vantage Partners

    Episode 4: Stuart Kliman, Vantage Partners

    In this Episode of Biotalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Stuart Kliman (skliman@vantagepartners.com), Founder and Partner at Vantage Partners, a global management consulting firm that specializes in the areas of negotiation and relationship management and in particular works with life sciences organizations to help them launch new alliances relationships to best results. They discussed the negotiation tactics and the differences between deal-minded and implementation-minded negotiating approaches in the spirit of optimizing alliance management and maximizing long-term deal value creation for life science companies.

    • 34 min
    Episode 3: Roger Longman, Real Endpoints

    Episode 3: Roger Longman, Real Endpoints

    In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making. Highlights of the conversation include:
    Major shifts in the pharmaceutical industry in recent decades Why pharmaceutical pricing and reimbursement became such a ‘hot button’ topic Trends towards value-based pricing and ‘pay for performance’ approached Recent high profile product launches and pricing decisions Implications of pricing / reimbursement environment on life science deal making and business development

    • 36 min
    Episode 2: Bradley Campbell, Amicus Therapeutics

    Episode 2: Bradley Campbell, Amicus Therapeutics

    In this episode of Biotalk podcast, Josh Hamermesh, Vice President of Locust Walk interviews Bradley Campbell, President& COO of Amicus Therapeutics. Amicus is very much at the forefront developing and commercializing important therapies to treat a range of devastating rare and orphan diseases. In fact, this has been an eventful and exciting week at Amicus as the company announced the launch of Galafold in the UK. Galafold is the first oral treatment as well as the first precision medicine product for patients with Fabry’s Disease patients.

    • 33 min
    Episode 1: Chris Ehrlich, Locust Walk

    Episode 1: Chris Ehrlich, Locust Walk

    Biotalk is a deal maker’s playbook to making an impact and generating returns in life sciences.  Our guest speakers are industry leaders and institutional and family office investors who share their experience and views on deal making and industry trends to educate and inform. 

    • 20 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Investing

Listeners Also Subscribed To